Israel Englander Sage Therapeutics, Inc. Transaction History

Millennium Management LLC

$175 Billion
Q1 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 309,540 shares of SAGE stock, worth $2.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

309,540

Previous 1,623,785 80.94%

Holding current value

$2.05 Million

Previous $8.82 Million 72.1%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$5.55 - $8.66 $7.29 Million - $11.4 Million	-1,314,245 Reduced 80.94%	309,540 $2.46 Million
Q4 2024 Feb 14, 2025	BUY	$4.78 - $8.57 $596,161 - $1.07 Million	124,720 Added 8.32%	1,623,785 $8.82 Million
Q3 2024 Nov 14, 2024	BUY	$7.02 - $13.08 $8.88 Million - $16.6 Million	1,265,376 Added 541.48%	1,499,065 $10.8 Million
Q2 2024 Aug 14, 2024	SELL	$10.58 - $17.9 $713,769 - $1.21 Million	-67,464 Reduced 22.4%	233,689 $2.54 Million
Q1 2024 May 15, 2024	SELL	$18.62 - $26.95 $596,771 - $863,747	-32,050 Reduced 9.62%	301,153 $5.64 Million
Q4 2023 Feb 14, 2024	SELL	$17.1 - $22.26 $1.45 Million - $1.89 Million	-84,907 Reduced 20.31%	333,203 $7.22 Million
Q2 2023 Aug 14, 2023	BUY	$40.65 - $59.54 $2.09 Million - $3.06 Million	51,447 Added 14.03%	418,110 $19.7 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $46.57 $10.5 Million - $13.1 Million	280,979 Added 327.92%	366,663 $15.4 Million
Q4 2022 Feb 14, 2023	BUY	$32.2 - $43.61 $1.27 Million - $1.72 Million	39,479 Added 85.44%	85,684 $3.27 Million
Q3 2022 Nov 14, 2022	SELL	$32.28 - $43.27 $1.05 Million - $1.41 Million	-32,628 Reduced 41.39%	46,205 $1.81 Million
Q2 2022 Aug 15, 2022	SELL	$27.52 - $37.99 $2.06 Million - $2.84 Million	-74,853 Reduced 48.71%	78,833 $2.55 Million
Q1 2022 May 16, 2022	BUY	$30.71 - $45.71 $3.9 Million - $5.8 Million	126,936 Added 474.53%	153,686 $5.09 Million
Q4 2021 Feb 14, 2022	SELL	$37.06 - $47.11 $4.55 Million - $5.79 Million	-122,818 Reduced 82.12%	26,750 $1.14 Million
Q3 2021 Nov 15, 2021	BUY	$40.26 - $57.37 $3.2 Million - $4.57 Million	79,583 Added 113.71%	149,568 $6.63 Million
Q2 2021 Aug 16, 2021	BUY	$54.88 - $79.29 $2.87 Million - $4.15 Million	52,348 Added 296.81%	69,985 $3.98 Million
Q1 2021 May 17, 2021	SELL	$70.65 - $96.76 $77,008 - $105,468	-1,090 Reduced 5.82%	17,637 $1.32 Million
Q4 2020 Feb 16, 2021	SELL	$58.41 - $89.06 $11 Million - $16.7 Million	-188,024 Reduced 90.94%	18,727 $1.62 Million
Q3 2020 Nov 16, 2020	SELL	$41.13 - $62.45 $3.89 Million - $5.9 Million	-94,465 Reduced 31.36%	206,751 $12.6 Million
Q2 2020 Aug 14, 2020	SELL	$25.95 - $43.15 $8.99 Million - $14.9 Million	-346,254 Reduced 53.48%	301,216 $12.5 Million
Q1 2020 May 14, 2020	BUY	$26.15 - $77.24 $15.3 Million - $45.1 Million	584,336 Added 925.55%	647,470 $18.6 Million
Q4 2019 Feb 14, 2020	BUY	$60.18 - $154.77 $2.08 Million - $5.36 Million	34,637 Added 121.55%	63,134 $4.56 Million
Q3 2019 Nov 14, 2019	BUY	$140.29 - $189.96 $4 Million - $5.41 Million	28,497 New	28,497 $4 Million
Q1 2019 May 14, 2019	SELL	$89.33 - $163.65 $11.5 Million - $21.1 Million	-128,822 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$81.94 - $139.71 $18.8 Million - $32.1 Million	-229,877 Reduced 64.09%	128,822 $12.3 Million
Q3 2018 Nov 14, 2018	SELL	$138.11 - $169.04 $2.93 Million - $3.58 Million	-21,205 Reduced 5.58%	358,699 $50.7 Million
Q2 2018 Aug 14, 2018	BUY	$140.36 - $175.76 $45.9 Million - $57.5 Million	327,312 Added 622.36%	379,904 $59.5 Million
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $265,806 - $336,000	1,747 Added 3.44%	52,592 $8.47 Million
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $3.09 Million - $8.51 Million	50,845	50,845 $8.38 Million

Others Institutions Holding SAGE

# of Institutions

219

Shares Held

51.2M

Call Options Held

220K

Put Options Held

312K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $393M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account